Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Chronic Rhinosinusitis With Nasal Polyposis
NCT07420257Phase 3Not yet recruiting
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of CM326 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by CSPC Baike Biopharmaceutical. Primary endpoints: Nasal Polyp Score at 24 weeks and Nasal Congestion Score at 24 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
CM326
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07420257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07420257.